Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yaz ad gets FDA-OK make-over

Executive Summary

Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August

You may also be interested in...



Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

Troubles Persist For Medtronic’s HeartWare Device As FDA Announces Another Class I Recall

It’s the third high-risk class I action in recent weeks related to the company’s HeartWare Ventricular Assist Device (HVAD) System. It’s also Medtronic’s sixth overall class I since the beginning of March.

Japan Helps Bayer’s Eylea Sales To Sparkle

Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.

Topics

UsernamePublicRestriction

Register

PS050675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel